Matt Surface - Scholarly Publications

1). Surface, M., Bawlwani, M., Waters, C., Haimovich, A., Gan-Or, Z., Marder, K.S., Hsieh, T., Song, L., Padmanabhan, S., Hsieh, F., Merchant, K.M., Alcalay, R.N. (2022) Reply to: “Could Blood Hexosylsphingosine Be a Marker for Parkinson's Disease Linked with GBA1 Mutations”? Mov Disord. DOI: 10.1002/mds.29136. PMID: 35980035
2). Avisar, H., Guardia-Laguarta, C., Surface, M., Papagiannakis, N., Maniati, M., Antonellou, R., Paradimitriou, D., Koros, C., Athanassiadou, A., Przedborski, S., Lerner, B., Stefanis, L., Area-Gomez, E., Alcalay, R.N. (2022). Lipid Level Alteration in Human and Cellular Models of Alpha Synuclein Mutations. npj Parkinson’s Disease. DOI: 0.1038/s41531-022-00313-y
3). Xu, Y., Feeney, M., Surface, M., Novak, D., Troche, M.S., Beck, J.C., Alcalay, R.N. (2022) Attitudes Toward Telehealth Services Among People Living with Parkinson’s Disease: A Survey Study. Mov Disord. DOI: 10.1002/mds.28990.
4). Dong, C., Honrao, C., Rodrigues, L.O., Wolf, J., Sheehan, K.B., Surface, M., Alcalay, R.N., O’Day, E.M. (2022). Plasma Metabolite Signature Classifies Male LRRK2 Parkinson’s Disease Patients. Metabolites. DOI: 10.3390/metabo12020149.
5). Surface, M., Bawlwani, M., Waters, C., Haimovich, A., Gan-Or, Z., Marder, K.S., Hsieh, T., Song, L., Padmanabhan, S., Hsieh, F., Merchant, K.M., Alcalay, R.N. (2022) Reply to: No Evidence that Glucosylsphingosine Is a Biomarker for Parkinson Disease. Mov Disord. DOI: 10.1002/mds.28936. PMID: 35092096.
6). Surface, M., Bawlwani, M., Waters, C., Haimovich, A., Gan-Or, Z., Marder, K.S., Hsieh, T., Song, L., Padmanabhan, S., Hsieh, F., Merchant, K.M., Alcalay, R.N. (2021). Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson’s Disease. Mov Disord. DOI: 10.1002/mds.28846. PMID: 34741486.
7). Xu, Y*., **Surface, M*.,** Chan, A.K., Halpern, J., Vanegas-Arroyave, N., Ford, B., Feeney, M.P., Kwei, K.T., Katus, L.E., Kuo, S., Shah, H., Waters, C., Winfield, L.M., Beck, J.C., Przedborski, S., Fahn, S., Alcalay, R.N. (2021) COVID-19 Manifestations in People with Parkinson’s Disease: a USA Cohort. J Neurol. DOI: 10.1007/s00415-021-10784-3. PMID: 34482434.
8). Avisar, H., Guardia-Laguarta, C., Area-Gomez, E., Surface, M., Chan, A.K., Alcalay, R.N., Lerner, B. (2021). Lipidomics Prediction of Parkinson’s Disease Severity: A machine-learning analysis. J Parkinsons Dis. DOI: 10.3233/JPD-202476. PMID: 33814463.
9). Feeney, M., Xu, Y., Surface, M., Shah, H., Vanegas-Arroyave, N., Chan, A.K., Delaney, E., Przedborski, S., Beck, J.C., Alcalay, R.N. (2021). The Impact of COVID-19 and Social Distancing on People with Parkinson’s Disease: A Survey Study. npj Parkinson’s Disease. DOI: 10.1038/s41531-020-00153-8. PMID: 33479241.
10). Yu, E., Rudakou, U., Krohn, L., Mufti, K., Ruskey, J.A., Asayesh, F., Estiar, M.A., Spiegelman, D., Surface, M., Fahn, S., Waters, C.H., Greenbaum, L., Espay, A.J., Dauvilliers, Y., Dupré, N., Rouleau, G.A., Hassin‐Baer, S., Fon, E.A., Alcalay, R.N. and Gan‐Or, Z. (2020). Analysis of Heterozygous PRKN Variants and Copy‐Number Variations in Parkinson's Disease. Mov Disord. DOI: 10.1002/mds.28299. PMID: 32970363.
11). Winter, S.V., Karayel, O., Strauss, M.T., Padmanabhan, S., Surface, M., Merchant, K., Alcalay, R.N., Mann, M. (2020). Urinary proteome profiling for stratifying patients with familial Parkinson’s disease. EMBO Mol Med. DOI: 10.15252/emmm.202013257. PMID: 33481347.